The results of the pathological stage analysis revealed that the patients with a higher proportion of CD86+CYPJ+ (M1 TAMs) macrophages or CD8+CYPJ+ T cells exhibited a lower pathological grade, indicating that CYPJ acted as a protective factor against liver cancer (Figure 7C). Here, CD86 is linked to liver cancer.